Abstract: A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.

Abstract: The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SA RS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL-6, Troponin T, and D-dimer.

Abstract: A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.

Abstract: Pharmaceutical compositions that include aqueous suspensions of a therapeutically effective quantity of a diaminopyrimidine compound (such as pyrimethamine) are provided herein. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical compositions and methods for preventing, treating, or alleviating cytokine release syndrome are described, the compositions comprising pentoxifylline and a pharmaceutically acceptable carrier. Methods for using such compositions are also described.

Abstract: Pharmaceutical compositions that include aqueous suspensions of a therapeutically effective quantity of a diaminopyrimidine compound (such as pyrimethamine) are provided herein. Methods for fabricating the compositions and using them are also described.

Abstract: Disclosed are methods, devices, and techniques useful for enhancing function of an organ or cellular graft through administration of light frequencies sufficient to enhance desired therapeutic activity. In one embodiment a bone marrow cellular population is treated with one or more wavelengths of low level laser irradiation at a sufficient energy to enhance engraftment, trophic, and regenerative activity in the corpus cavernosum. In another embodiment the recipient penile body is treated with one or more wavelengths of low level laser irradiation at a sufficient energy to enhance chemoattraction and growth factor secretion.

Abstract: Therapies for treating erectile dysfunction using regenerative cells and therapeutic energy treatments are disclosed herein. Said therapeutic energy treatments can be selected from one or more of the following methods: electrical stimulation/electroacupuncture, low-level laser irradiation, and extracorporeal shockwave therapy. The combination treatments described herein are useful for restoring components of the penile anatomy that are associated with erectile dysfunction, in particular, nerves, blood vessels and/or smooth muscle cells.

Abstract: Disclosed are compositions of matter useful for treating anxiety and depression. In one embodiment a nutraceutical composition is administered to a patient in need of said composition comprising of the following combination of ingredients: niacin, magnesium, ashwagandha, passionflower, skullcap, St.